A5080823558- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- PI3K/AKT/mTOR signaling in cancer
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Viral-associated cancers and disorders
- Chemokine receptors and signaling
- Immune Response and Inflammation
- Advanced Breast Cancer Therapies
- Immune Cell Function and Interaction
- Ubiquitin and proteasome pathways
- Lung Cancer Treatments and Mutations
- Acute Myeloid Leukemia Research
- Lung Cancer Research Studies
- T-cell and Retrovirus Studies
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Phase-change materials and chalcogenides
- Inflammation biomarkers and pathways
- Kruppel-like factors research
- Cancer, Stress, Anesthesia, and Immune Response
- Natural Compounds in Disease Treatment
- Cancer Treatment and Pharmacology
Kaifeng City Children's Hospital
2025
Changzhou University
2024
Jiangxi Science and Technology Normal University
2024
Sanya University
2024
Hainan University
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2023
Institute of Hematology & Blood Diseases Hospital
2023
National Clinical Research
2023
Leipzig University
2022
Universidade Federal de Viçosa
2022
Abstract Purpose: To investigate the efficacy and safety of novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments. Patients Methods: Histologically confirmed FL disease progression after receiving second-line or greater therapy were enrolled. Linperlisib was administered 80 mg every day, a 28-day cycle until intolerable toxicity occurred. The primary outcome for study objective response...
Clinical trials of immunotherapy in mantle cell lymphoma have not yet delivered desirable results, partly because the inhibitory machinery tumor and its microenvironment. Here we investigated role B7-H1, a member B7 family co-stimulatory/co-inhibitory ligands, lymphoma-mediated immunosuppression. Allogeneic CD3+, CD4+ CD8+ T cells were purified co-cultured with irradiated cells. Mantle lymphoma-reactive T-cell lines from HLA-A*0201+ healthy blood donors generated after vitro restimulation,...
This investigation assessed the therapeutic potential of combining linperlisib, a targeted inhibitor phosphatidylinositol 3-kinase delta (PI3Kδ), with gemcitabine and oxaliplatin (GEMOX) for patients relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). was multicenter, phase Ib/II clinical study conducted across six sites in China, enrolling 39 individuals histologically confirmed R/R DLBCL. The treatment protocol included oral linperlisib alongside GEMOX administered...
Mục tiêu: Khảo sát thành phần hóa học có trong lá Hải kim sa (Ligodium japonicum) và hoạt tính ức chế enzyme angiotensin-converting, lipase từ các cao phân đoạn của sa. Đối tượng phương pháp: Nghiên cứu xác định hợp chất dược liệu bằng pháp học. Sử dụng chiết cao, đánh giá khả năng (angiotensin-converting lipase) toàn phần, n-Hexan, chloroform, n-Butanol nước ở mức độ in vitro. Kết quả: Thành gồm nhóm alkaloid, flavonoid, coumarin, saponin, antranoid, triterpenoid, tanin, acid hữu cơ,...
Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- lymphomas, but as a drug class, these agents have frequently been observed tolerability limitations. Next-generation that improve the while maintaining efficacy are desirable.
Multiple myeloma (MM) is an incurable B-cell malignancy characterized by accumulation of malignant plasma cells in the bone marrow and recurrent or persistent infections. Toll-like receptors (TLRs) are essential host defense against The aim this study was to investigate TLR initiated responses MM including proliferation, anti-apoptosis immune escape. Myeloma cell lines gene transcription, cycle protein expression were detected RT-PCR, real-time PCR, western blot, ELISA flow cytometry...
Abstract Chitin and phytic acid are abundant sustainable resources commonly found in shrimp shells, crab various plants. However, they underutilized, their biomass value is frequently underestimated. To address this, the current study developed a strategy to synthesize efficient separator coatings for zinc-iodine (Zn-I) batteries using chitin as carbon sources (biochar). First, nanosheets of porous doped with N P (NP-PC), featuring multiple active sites, synthesized through situ...
YY-20394, a highly selective PI3Kδ inhibitor, is under NDA submission for treating follicular lymphoma in China. The absorption, metabolism, and excretion of YY-20394 were evaluated healthy Chinese male subjects following single oral dose 80 mg [14C]YY-20394 (100 µCi).Within 264 h post-dose, 92.1% the administered was recovered, with 58.1% from urine 34.0% faeces. rapidly absorbed humans, peak plasma concentrations occurred at 1.0 h. drug fraction least according to recovery.In addition...
7531 Background: PI3Kδ inhibitors have been shown to important roles in blocking mitogenic and survival signaling within the tumor cell microenvironment activate antilymphoma immune responses. Linperlisib is an oral highly selective small molecule inhibitor of has demonstrated be well-tolerated with a favorable PK profile patients lymphomas at RP2D. This phase Ib study evaluating efficacy safety relapsed or refractory peripheral T-cell lymphoma (PTCL), aggressive malignancy few treatment...
3098 Background: Transforming growth factor beta (TGF-β) is upregulated in the majority of tumors, promoting tumor cell proliferation, differentiation, and, modulation microenvironment. YL-13027, a small molecule inhibitor type 1 receptor TGF-β, potent highly selective oral agent that downregulates TGFbR1-dependent pathways cells. YL-13027 dosed into bearing animals drives inhibition and interruption metastasis. In this first-in-human phase1 study, we characterized safety, tolerability,...
This method produces microcapsules that possess a high thermal rate and good UV absorption fluorescence properties, making them suitable for use in fluorescent buildings, textiles, coatings, other applications.
<div>AbstractPurpose:<p>Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- lymphomas, but as a drug class, these agents have frequently been observed tolerability limitations. Next-generation that improve the while maintaining efficacy are desirable.</p>Patients Methods:<p>A phase Ib clinical study was conducted...
<p>Figure and Tables</p>
Patients with advanced solid tumors have a suboptimal prognosis. This study investigated the safety and feasibility of linperlisib, selective phosphatidylinositol 3-kinase delta isoform (PI3Kδ) inhibitor, for treating patients tumors. In this phase Ib, single-arm, open-label, multi-center clinical trial, histologically confirmed from eight centers in China were enrolled to receive oral linperlisib (80 mg/day). The primary endpoint was safety. Between August 2019 June 2022, 94 trial received...
7563 Background: YY-20394, an oral highly selective PI3Kδ inhibitor was studied in a phase I trial for patients with relapse or refractory B-cell malignancies. We characterized the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK) and preliminary efficacy of YY-20394. Methods: YY-20394 given orally once daily (QD) 28 days cycle until disease progression, unacceptable toxicity, withdrawal from study. Only 1 subject treated starting 20 mg daily, then subsequent cohorts...
Purpose: To evaluate the efficacy and toxicity of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every 2 weeks on previously untreated advanced colorectal cancer patients in Chinese population. Patients methods: Forty-nine were enrolled to receive, entirely as inpatients, 2-weekly cycles 85 mg/m2 i.v. over hours Day 1, together 200 hours, 5-FU 400 mg/m2, bolus, followed by a 22-hours infusion at 600 Days 1–2 (FOLFOX4) weeks. Treatment was given until progression or...